Currently, several conventional clinical drugs, such as the liver cancer‐targeting drug sorafenib and the anti‐inflammatory drug for inflammatory bowel disease, sulfasalazine, promote tumor cell ferroptosis by targeting key signaling pathways like Glutathione Peroxidase 4 (GPX4). The gene discussed is GPX4; the disease is inflammatory bowel disease.